Upholding the tenet“taking science and technology as driving power”, Novpharm is devoted to the research and development of new products. Our products include Febuxostat and its intermediates (including ethyl 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylate), Dronedarone intermediates (including 2-butyl-5-nitrobenzofuran, 2-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran, and N-(3-Chloropropyl)dibutylamine), Agomelatine intermediates, Perindopril intermediate(including L-norvaline), Nequinate, etc. , all of which were developed independently by our own research group and have been brought into mass production.

At present, NovPharm has offered high-quality Contract R&D Service and corresponding industrial production of novel drugs and the intermediates thereof to many multinational pharmaceutical companies in Europe, US, India, etc., and has become the long-term supplier of these companies. With its high-quality products sold world-wide, the company has built up a good business credit and company image in the field.

With strong research capabilities and spirit of innovation, the company has committed long-term cooperation with many famous domestic universities and research institutions, and established state-of-the-art R&D centers. Every year, NovPharm develops new market oriented high-technology products at the forefront of advanced technology.

Insisting on the management policy of“Product Quality is the Basis for the Survival and Development of the Company”, NovPharm forms an effective process control system and standard quality management system to ensure that our products and services are in accordance with the ever changing international standard. We will wholeheartedly provide high-quality products with competitive price and highly efficient services with science and technology innovation to clients across the globe.